Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for ...

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasisTop-line data from the 12-week double-blind ...

Systemic biologics are better for cases of psoriasis that do not resolve with lower-potency topicals, so the patient can avoid applying high-potency drugs over large areas of the body.

Oral, once-daily doses of VYN202 being evaluated in subjects with moderate-to-severe plaque psoriasis Top-line data from the 12-week double-blind trial expected by year-end 2025 Phase 1b trial designe ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission (EC) granted marketing authorisation in the ...

Aloe vera isn't just for sunburns. Experts suggest it can also be helpful in the fight against acne too, thanks to its ...

Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

The Generalized Pustular Psoriasis (GPP) market is driven by the increasing adoption of non-invasive and minimally invasive treatment options such as topical biologic therapy, phototherapy, and laser ...

The global injectable drug delivery devices market size is calculated at USD 565 billion in 2025 and is expected to reach around USD 1,217 billion by ...

Immune checkpoint inhibitors for patients with cancer may be associated with an increased risk for psoriasis when compared ...